Impax/Teva Wellbutrin SR Generic Cleared To Launch By Court, FDA
Impax' bupropion sustained-release generic is cleared for launch following an appeals court ruling that the company does not infringe GlaxoSmithKline's Wellbutrin SR/Zyban patent
You may also be interested in...
Eon's launch of generic bupropion extended-release 100 mg (GlaxoSmithKline's Wellbutrin SR) depends on the resolution of two temporary restraining orders: one from GSK and one from Andrx
A federal appeals court decision in the Festo case further clarifies the circumstances under which pharmaceutical patent holders can assert infringement claims under the doctrine of equivalents
An appeals court ruling for GlaxoSmithKline in Wellbutrin SR patent litigation against Andrx finds the district court erred in its construction of GSK's patent claims